WENA: anewmeds.com Kapitalizatsiya va daromad nisbati
Anew Medical, Inc. (WENA) vektor ishlab chiqarishni autsorsing qilish orqali xarajatlarni optimallashtirmoqda, shu bilan birga uning noyob patentlari kompaniyani narxlar bosimidan himoya qiladi. P/S koeffitsiyenti grafigi adolatli baholash diapazonlarini aniqlash imkonini beradi, bunda 0.00 ko'rsatkichi metrikaning holatini ifodalaydi. Anew Medical, Inc. (WENA) Parkinson va Altsgeymer kasalliklariga qarshi kurashish uchun innovatsion gen terapiyalarini yaratish orqali neyrodegeneratsiyani to'xtatishni maqsad qilgan.
Anew Medical, Inc. (WENA) kompaniyasi koʻrsatkichlari kesimi va tahlili
- joriy kotirovkalar va o'rtacha qiymat prognozi:
- bozor kapitallashuvi haqida ma'lumot:
- biznesning balans baholash tafsilotlari:
- qarz majburiyatlari va likvidlik statistikasi:
Umumiy qarzning kapitalga nisbati Anew Medical, Inc.|WENA - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzning o'z kapitaliga nisbati anewmeds.com|WENA - Kompaniyaning umumiy qarzi|Qarzning sof aktivlarga nisbati Anew Medical|WENA - Kompaniyaning uzoq muddatli qarzlari|Qisqa muddatli qarz hajmi Anew Medical|Shoshilinch likvidlik koeffitsiyenti anewmeds.com
- sof foyda va baholash koeffitsiyentlari ma'lumotlari:
WENA - Sof foyda|Kelajakdagi foyda Anew Medical, Inc.|WENA - Narx-foyda koeffitsiyenti|Kapitalizatsiyaning prognoz qilingan foydaga nisbati Anew Medical Inc.|WENA - Narx-foyda va o‘sish multiplikatori|Korxona qiymatining foizlar, soliqlar va amortizatsiyadan oldingi foydaga nisbati koeffitsiyenti Anew Medical|WENA - EBITDA operatsion foydasi|So'nggi o'n ikki oy davomida bitta aksiya uchun sof foyda Anew Medical|WENA - So'nggi o'n ikki oy davomida bir aksiya uchun foyda|So'nggi 12 oy davomida bir aksiya uchun foydaning yillik o'sishi anewmeds.com|WENA - Joriy yilda foyda o'sishi|Keyingi yil uchun foyda o'sishi prognozi Anew Medical, Inc.
- emitentning tushumi va sotuvlari tafsilotlari:
Kompaniyaning jamlanma tahliliyoti:Anew Medical Inc., WENA
Geopolitik beqarorlik va logistik uzilishlar sharoitida nevrologik kasalliklar terapiyalarini ishlab chiqishning o'ziga xos xususiyatlari Anew Medical, Inc. (WENA) daromadini hayotiylikning asosiy ko'rsatkichiga aylantiradi. Sotuvlar nisbatidagi narx koeffitsiyentini tahlil qilish orqali investor biznesning bozor qiymatini sotuvlar hajmi bilan nisbatda baholaydi, bu esa aktiv uchun haddan tashqari ko'p to'lov qilinganlik darajasini aniqlash yoki iqtisodiy siklning turli bosqichlarida kompaniyaning qadrsizlanganini aniqlash imkonini beradi.
Raqobatdosh kompaniyalar
BIIB - Sotuvga nisbatan narx|P/S multiplikatori NBIX (Neurocrine Biosciences, Inc.)|RGC: Kapitalizatsiya va daromad nisbati|Axsome Therapeutics Inc - P/S multiplikatori|Narx/daromad koeffitsiyenti ACADIA Corp ACAD|XENE: P/S multiplikatori|Kapitalizatsiyaning daromadga nisbati vikingtherapeutics.com|SUPN (Supernus) - P/S multiplikatori|P/S multiplikatori Catalyst Pharma|Narxning daromadga nisbati Denali Therapeutics Inc (DNLI)|Narxning daromadga nisbati HRMY (Harmony Corp)|Biohaven Ltd. - Kapitalizatsiyaning daromadga nisbati|Bozor kapitallashuvining daromadga nisbati AMLX|Trevi Therapeutics, Inc. - P/S multiplikatori|Narx/daromad koeffitsiyenti Praxis Precision Medicines Inc PRAX|Anavex Corp (AVXL) - Narxning daromadga nisbati|Kapitalizatsiya va daromad nisbati CBLL|PRTA (Prothena Biosciences) - P/S multiplikatori|Kapitalizatsiyaning daromadga nisbati Alector Therapeutics (ALEC)|Kapitalizatsiyaning daromadga nisbati ANNX (Annexon)|Narx/daromad koeffitsiyenti omeros.com|Neurogene Corp - Kapitalizatsiyaning daromadga nisbati|ACIU - Kapitalizatsiyaning daromadga nisbati|Voyager Therapeutics - P/S multiplikatori|Sotuvga nisbatan narx neumoratx.com|Scilex (SCLX) - Narxning daromadga nisbati|Kapitalizatsiya va daromad nisbati TVGN|ACOG (Alpha Cognition Inc) - P/S multiplikatori|P/S multiplikatori Cognition Therapeutics Inc.|Narxning daromadga nisbati Inhibikase Therapeutics (IKT)|cassavasciences.com - Kapitalizatsiya va daromad nisbati|P/S multiplikatori ASRT (Assertio)|Coya Therapeutics Inc (COYA) - Sotuvga nisbatan narx|VTGN: Kapitalizatsiyaning daromadga nisbati|OVID - P/S multiplikatori|Acumen Pharmaceuticals (ABOS) - Narxning daromadga nisbati|cervomed.com - Bozor kapitallashuvining daromadga nisbati|Narxning daromadga nisbati Alterity Therapeutics Ltd.|Sotuvga nisbatan narx Clene Nanomedicine CLNN|P/S multiplikatori PEPG|P/S multiplikatori Jupiter Neurosciences, Inc. (JUNS)|Narxning daromadga nisbati Relmada Therapeutics RLMD|ANVS: Kapitalizatsiya va daromad nisbati|Grace Tx - P/S multiplikatori|Sotuvga nisbatan narx Firefly Neuroscience, Inc.|KLTO (anewmeds.com) - Kapitalizatsiyaning daromadga nisbati|Kapitalizatsiyaning daromadga nisbati NeuroSense Therapeutics Ltd.|Kapitalizatsiyaning daromadga nisbati RVPH|MTVA: Bozor kapitallashuvining daromadga nisbati|Narxning daromadga nisbati NeurAxis (NRXS)|Kapitalizatsiyaning daromadga nisbati heliusmedical.com HSDT|P/S multiplikatori PASG (Passage Bio)|Neuphoria Therapeutics, Inc. (NEUP) - Sotuvga nisbatan narx|Minerva Neurosciences - P/S multiplikatori|ATHA (athira.com) - Kapitalizatsiya va daromad nisbati|ADXN: P/S multiplikatori|ALZN - Narx/daromad koeffitsiyenti|CYCN (Cyclerion Therapeutics Inc.) - P/S multiplikatori|Kapitalizatsiyaning daromadga nisbati Protagenic (PTIX)|P/S multiplikatori KTTA|P/S multiplikatori cortigent.com (CRGT)|Narxning daromadga nisbati Avenue Therapeutics, Inc. ATXI|Brainstorm Cell Therapeutics Inc. - Narxning daromadga nisbati|CARA: Kapitalizatsiyaning daromadga nisbati|Bozor kapitallashuvining daromadga nisbati CHRO (Chromocell)|ELYM: P/S multiplikatori|ITCI - Narx/daromad koeffitsiyenti|Narxning daromadga nisbati Longboard Pharmaceuticals, Inc.|Kapitalizatsiya va daromad nisbati MRNS (Marinus Pharmaceuticals Inc)|P/S multiplikatori NKGN|Kapitalizatsiyaning daromadga nisbati NeuroBo Pharma NRBO|Sage Therapeutics, Inc. - Kapitalizatsiyaning daromadga nisbati|Narx/daromad koeffitsiyenti synaptogen.com (SNPX)|TRVN: Kapitalizatsiyaning daromadga nisbati|Vigil Neuroscience (VIGL) - Kapitalizatsiyaning daromadga nisbati|CERE: P/S multiplikatori
